Camurus’ second CRL for acromegaly drug; Teva details workforce cuts

Camurus’ second CRL for acromegaly drug; Teva details workforce cuts; news about a drug shortages report; and Axplora shifting manufacturing of ursodeoxycholic acid. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…

Ayisha Sharma · 2026-06-11

Plus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer. The ...

Source: Endpoints News